Some vials in two lots of the antibiotic cefazolin are labeled as being penicillin G potassium, which if used could lead to suboptimal outcomes, adverse events, drug interactions and delayed recovery.
Sandoz is recalling an additional lot of the antibiotic Cefazolin for Injection, 1 gram per vial, updating its recall from June 27, 2025. Some vials in this lots have been incorrectly labeled as Penicillin G Potassium for Injection, USP, 20 million Units. Sandoz has confirmed that the vials incorrectly labeled as penicillin G potassium actually contain cefazolin.
Administering cefazolin instead of penicillin G potassium could lead to lack of efficacy, less than optimal treatment of severe infections, antibiotic resistance, adverse reactions, severe allergic reactions (e.g., anaphylaxis), drug interactions and delayed recovery, according to the new recall notice.
Sandoz has received a complaint of administration of the incorrectly labeled product to a patient, but the company has not received any reports of adverse events or injuries related to the product mislabeling.
Both cefazolin and penicillin G potassium belong to the beta-lactam group of antibiotics, but they are indicated for different types of infections, and the spectrum of susceptible organisms also differs.
Cefazolin for Injection USP is used to treat infections, including pneumonia, as well as to prevent infections before and after surgery. Penicillin G Potassium for Injection is indicated to treat serious infections, including septicemia and skin and wound infections. It is also approved to treat diphtheria, community-acquired pneumonia, peritonitis, meningitis/brain abscesses, osteomyelitis, infections of the genital tract, anthrax, tetanus, gas gangrene, listeriosis, pasteurellosis, rat bite fever, fusospirochetes, actinomycosis, complications in gonorrhea and syphilis and Lyme.
The recalled lots and vials are:
Get the latest industry news, event updates, and more from Managed healthcare Executive.
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More